Drugs / Ad-ISF35
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00850057 | Feb 2006 → Oct 2009 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of California, San Diego | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-ISF35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00850057 ↗ |
| Known as | ISF35 | “Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).” NCT00850057 ↗ |
| Route | Other | “injected directly into the lymph nodes” NCT00850057 ↗ |